XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Total revenues $ 26,174 $ 20,741
Cost of revenues:    
Total cost of revenues 10,549 7,737
Gross profit 15,625 13,004
Operating expenses:    
Research and development 13,700 8,438
Sales and marketing 4,789 5,093
General and administrative 8,936 5,086
Total operating expenses 27,425 18,617
Loss from operations (11,800) (5,613)
Other (expense) income:    
Change in fair value (3,079) (627)
Interest income 699 438
Total other expense (2,380) (189)
Loss before income taxes (14,180) (5,802)
Income tax expense 91 46
Net loss (14,271) (5,848)
Net loss attributable to noncontrolling interest (445) (54)
Net loss attributable to Schrödinger common and limited common stockholders $ (13,826) $ (5,794)
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: $ (0.34) $ (0.98)
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: 40,666,970 5,938,260
Software Products and Services    
Revenues:    
Total revenues $ 23,812 $ 18,605
Cost of revenues:    
Total cost of revenues 4,001 3,133
Drug Discovery    
Revenues:    
Total revenues 2,362 2,136
Cost of revenues:    
Total cost of revenues $ 6,548 $ 4,604